The clinical impact of androgens in endometrial cancer: cancer promoter or suppressor?
Endocrine Oncology · 01.01.2026 · 6 (1)
DOI: 10.1530/eo-25-0040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Oncology, online erschienen am 11.03.2026. Verfasst von Xirong Wu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
Androgens are associated with the risk of endometrial carcinoma (EC). However, their roles as prognostic factors are less clear. This study aims to investigate the prognostic impact of different androgens.
Methods
We conducted a retrospective cohort study of patients who had previous endometrial sampling that showed EC between August 19, 2003, and November 4, 2015. This study included 465 patients with an average follow-up of 37 months. We examined associations between endogenous testosterone levels (total, bioavailable and free testosterone) and the clinical outcomes in patients with EC. Serum levels of bioavailable testosterone were calculated using the total testosterone level and the sex hormone-binding globulin concentration (measured by chemiluminescent and radioimmunoassays, respectively).
Results
Higher circulating concentrations of total and bioavailable testosterone were associated with a higher risk of type I endometrial cancer (OR = 1.015, 95% CI: 1.008–1.022; OR = 1.395, 95% CI: 1.266–1.536, respectively), but the similar association was not found in type II patients (OR = 1.009, 95% CI: 0.998–1.020; OR = 1.208, 95% CI: 0.998–1.461, respectively). However, higher levels of testosterone in EC patients correlated with favorable clinicopathological features, especially bioavailable and free testosterone. Furthermore, Kaplan–Meier survival analysis indicated that elevated bioavailable and free testosterone levels were associated a longer overall survival (P = 0.048, P = 0.036, respectively), but this trend was not statistically significant after adjustment for other prognostic factors (P = 0.312, P = 0.272, respectively).
Conclusion
Elevated serum testosterone levels were associated with an increased risk of type I cancers. Although androgens showed certain prognostic values, they were not independent prognostic factors. Different androgenic indexes showed different clinical implications. The risk estimates could refer to total and/or bioavailable testosterone. Bioavailable and/or free indexes may be better markers for the probable prognostic effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China.
- Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Gynecology and Obstetrics, Affiliated Hospital of Nantong University, Nantong, China.
ORCID-Profile: Xirong Wu, Wenyan Tian, Yingmei Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, X., Tian, W., & Wang, Y. (2026). The clinical impact of androgens in endometrial cancer: cancer promoter or suppressor?. Endocrine Oncology, 6(1). https://doi.org/10.1530/eo-25-0040
Vancouver
Wu X, Tian W, Wang Y. The clinical impact of androgens in endometrial cancer: cancer promoter or suppressor?. Endocrine Oncology. 2026;6(1). doi:10.1530/eo-25-0040
BibTeX
@article{Wu2026,
author = {Wu, Xirong and Tian, Wenyan and Wang, Yingmei},
title = {The clinical impact of androgens in endometrial cancer: cancer promoter or suppressor?},
journal = {Endocrine Oncology},
year = {2026},
volume = {6},
number = {1},
doi = {10.1530/eo-25-0040}
}
EUVIMED